医疗系统软件开发公司:iCAD, Inc.(ICAD)

  • A+
所属分类:医疗设备 软件开发

iCAD, Inc.(NASDAQ:ICAD)创立于1984年,前称Howtek, Inc.,于2002年2月改为现用名,总部位于美国新罕布什尔州Nashua,全职雇员11人,是一家软件公司,提供图像分析,工作流程解决方案和医疗成像系统支援软件,以便在美国和国际上早期识别和治疗癌症。

医疗系统软件开发公司:iCAD, Inc.(ICAD)

iCAD, Inc.(ICAD)美股百科:

iCAD公司分为2给部门来运作:Cancer Detection(癌症检测)和Cancer Therapy(癌症治疗)。

iCAD公司产品包括:

1. 电子近程治疗(eBX)产品,包含Axxent eBx systems用于治疗早期乳癌、子宫内膜和子宫颈癌、皮肤癌,以及治疗其他癌症或需要放射治疗的情况,包括手术时的放射治疗。

2. 数字乳房摄影电脑辅助检测(CAD)产品,例如乳房影像高阶影像分析及工作流程解决方案,包含SecondLook digital CAD systems,可检测及识别可疑块状和微钙化;PowerLook Advanced Mammography Platform为位于客户端网络的电脑服务器,接收患者影像模式研究、执行CAD分析,并发送CAD结果至影像储存及通信系统或审查工作站。

3. 数位乳房摄影CAD产品,包括用于检测乳房和前列腺癌的磁共振影像产品;乳房断层系统;电脑断层摄影(CT)大肠造影检查的高阶影像分析和工作流程解决方案,包括VeraLook,可支援结合大肠造影检查的结肠息肉检测。

iCAD公司服务于医院、门诊护理中心、独立肿瘤放射治疗单位和其他医疗办公室。

iCAD, Inc.主要通过销售组织,以及各种代工制造商伙伴、分销商和经销商销售其产品。

此外,iCAD公司与Invivo Corp.签署有战略合伙协议。

iCAD, Inc.(ICAD)美股投资:

  • 参考资料:
行情=点击直达行情=财报=财报日及评级=
百科==美股百科==机构==前10大股东==
官网==公司官网==分析==财报及其他==

weinxin
美股百科微信公众号
扫一扫或微信搜索公众号"美股百科",关注本站,获得最新美股资讯及美股IPO信息。美股百科,不见不散!
  • 版权声明:本站原创文章,于十二月 2, 201817:36:34,由 美股百科 发表,共 806 字,转载须授权!
  • 本站(www.mg21.com)旨在提供各上市公司基本面资料,供美股投资者参考。我们对任何公司或其股票,及任何投资产品(ETF等)的介绍均不构成任何投资建议,文末部分的股票评级均由各大券商发布,本站不对数据的可靠性负任何责任,据此操作,后果自担。请阅读:免责声明

发表评论

:?: :razz: :sad: :evil: :!: :smile: :oops: :grin: :eek: :shock: :???: :cool: :lol: :mad: :twisted: :roll: :wink: :idea: :arrow: :neutral: :cry: :mrgreen:

目前评论:7   其中:访客  7   博主  0

    • 美股之家 美股之家 9

      iCAD was founded in 1984 as Howtek, Inc. Howtek developed, manufactured and marketed digitizing systems or scanners. The scanners converted printed, photographic and other hard copy images to digital form for use in the graphic arts, photo finishing and medical industries. From 1984 to 2000 Howtek successfully developed a series of products that improved the quality of digital imaging while reducing the price and complexity of digitizing systems. In 2001, foreseeing a decline in the graphic arts and photo finishing industries, Howtek elected to focus solely on the medical imaging market. The company acquired Intelligent Systems Software, Inc. (ISSI) which had developed an approved computer-aided detection system for breast cancer. Subsequently, the company acquired Qualia Computing, Inc. of Ohio and its subsidiary, CADx Systems, Inc. These acquisitions brought together two of the three companies with FDA clearance to market CAD solutions for breast cancer in the United States.

      • 美股之家 美股之家 9

        iCad originally focused on image-analysis products designed to help radiologists and other health-care providers detect cancers early. In December 2010, iCAD expanded the company’s oncology footprint by acquiring Xoft, Inc. It acquired Xoft’s Axxent system which delivers radiation therapy directly to cancer sites with minimal radiation exposure to surrounding healthy tissue, according to the company. The system was approved in the U.S. for early-stage breast cancer, endometrial cancer and skin cancer, as well as other varieties where radiation therapy is indicated, the initial report on the acquisition stated. The shield used in the system had been cleared by the Food and Drug Administration (FDA) in June 2009 in an abbreviated process used for devices that are considered equivalent to products already on the market. That process, known as 510(k), takes less time than the procedure used to approve a new device, and it generally does not require tests on humans.”

        • 美股之家 美股之家 9

          iCAD continues to experience a period of growth in its cancer therapy business. Radiation treatment for breast, skin and gynecological cancers is moving from conventional external beam therapy to shorter duration, more targeted therapy. The advantages of the Xoft System, which is FDA cleared for treatment anywhere in the body, have significant potential to improve patient care and quality of life.

          iCAD is also applying its patented technology and algorithms to the development of CAD solutions for use with digital mammography and CT Colonography (CTC). The company is also increasing distribution through large OEM partners, such as General Electric (GE).

          • 美股之家 美股之家 9

            Within a week of iCAD’s closing on the Xoft acquisition, the Axxent FlexiShield Mini, used with its portable radiation device, the Axxent Electronic Brachytherapy System, was found to have left test subjects “riddled … with hundreds of tiny particles of the heavy metal tungsten in their breast tissue and chest muscles.” Twenty-seven of the cases occurred at Hoag Memorial Hospital Presbyterian in Newport Beach, Orange County, California. Eleven of those women have had mammograms, and all 11 showed tungsten. Two other women were treated in a study at Karmanos-Crittenton Cancer Center in Rochester Hills, Michigan. Full implications of the mistake had not been determined as of mid-March, 2011, but the company and the FDA had executed a recall on the FlexiShield Mini and were investigating.

            • 美股之家 美股之家 9

              Swedish Covenant Hospital in Chicago offered Xoft’s Axxent Electronic Brachytherapy System treatment, beginning in 2008. The hospital did not participate in the study in which the Axxent FlexiShield Mini — the device that has been recalled — was used in conjunction with intraoperative breast irradiation, nor has the hospital used the Axxent FlexiShield Mini on any patients.

              Starting in February, 2011, a series of parallel product liability suits have been filed in Orange Country Superior Court, totaling ten Jane Doe complainants and a number of John Doe spouses by August, 2011, per the September 30, 2011 10-Q filing by the company. The first and later of the plaintiffs, who consented to the experimental treatment, were represented by lawyer Jeff Milman.

              In July 2011, Zach’s Investment Research initiated coverage of the stock with a neutral rating and “positive on iCAD’s fundamentals” but said “we believe caution is warranted until there is more clarity on the potential and likely liability related to a recently filed product liability lawsuit”. While the company reported “strong revenue growth” for the first nine months of 2011, it also reported lawsuit and other legal expenses of $1.5 million as a component of a “Non GAAP Adjusted EBITDA” of negative $6.8 million.

              In January 2013, an Inflection Point Investing stock analyst wrote in part, under “Risks”: “Potential legal liability for a third-party related recall for a Xoft accessory product remains a small concern. We do not feel that this risk is material or anything to dwell upon.”

              • 美股之家 美股之家 9

                In November, 2012, the company’s products were granted a more-than-doubled reimbursement rate from U.S. Centers for Medicare & Medicaid Services “for the Company’s Xoft Axxent Electronic Brachytherapy System”. The news led to a spike in stock volume and the price began to move, more than doubling by mid-January 2013. At that time, noting the move already made by the stock, a stock analyst reviewed the company’s history and situation. With standard caveats, the analyst wrote that recent developments “could cause shares to double in a year and potentially triple over the next 24 months”.

                • 美股之家 美股之家 9

                  In calendar year 2016 fourth quarter, iCAD lost $3.3 million versus the $2.4 million lost in the previous-year same period. Revenue during the quarter dropped 8.95 percent to $6.93 million from $7.61 million in the previous year period. Debt was $0.2 million as on Dec. 31, 2016, down 83.98 percent from a year earlier, while cash and cash equivalents stood at $8.6 million at quarter/year end.